Overall, these data suggest that enriched TRIB2 and MAP3K1, which could be used to predict the efficacy of routine adjuvant treatment for glioma, may indicate increased resistance to TMZ and radiotherapy. This evidence concerns the gene TRIB2 and central nervous system cancer.